PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today the presentation of six new studies demonstrating the EOS System’s ability to achieve superior measurement accuracy for total hip arthroplasty (THA) pre-surgery planning, functional post-surgery implant positioning evaluation and long-term monitoring. The studies were presented at the 27th Annual Congress of the International Society for Technology in Arthroplasty (ISTA), which took place September 24-27 in Kyoto, Japan.
ISTA is an annual congress focused exclusively on arthroplasty and attracts the field’s leading surgeons, researchers and device makers from around the world. Of the six studies that the Company presented at ISTA, two studies in particular highlight the superiority of EOS for preoperative planning in 2D and 3D.
Professor Didier Mainard of Nancy University Hospital in France, reviewed results from a preliminary 31-patient study using the EOS System in conjunction with its novel 3D imaging software, hipEOS, for pre-operative planning in THA cases. The study demonstrated that EOS 3D imaging and hipEOS software significantly improves the accuracy of implant sizing over 2D imaging, while also exposing patients to a lower-dose of radiation when compared with conventional X-rays.
A 40-patient study presented by Dr. Esposito from the Hospital for Special Surgery in New York compared the EOS System with conventional 2D imaging for preoperative digital templating for THA. The data showed that EOS successfully predicted the exact size of femoral and acetabular implants respectively 27% and 22% more often than with conventional 2D imaging.
Additional studies presented at ISTA demonstrate the important benefits of EOS’ technology in pre-surgical evaluation and post-operative surgical assessment in 3D.
EOS imaging CEO, Marie Meynadier, commented: “The findings presented at ISTA 2014 highlight EOS’ performance advantages for both pre-surgery planning and post-operative evaluation. The accuracy of EOS clinical parameters not only has the potential to improve patient outcomes, but it can also lower healthcare costs by optimizing the implant size selection and positioning. We look forward to a growing adoption of the EOS 2D/3D imaging technology in large joint surgery.”
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 3rd quarter of 2014, on October 22, 2014 (after market).